nab-paclitaxel

Bristol Myers Squibb (BMS) is a leading global biopharmaceutical company that specializes in the discovery, development, and delivery of innovative medicines for serious diseases. The company is particularly prominent in the fields of oncology, hematology, immunology, and cardiovascular disease. BMS is the manufacturer of Abraxane (nab-paclitaxel), a chemotherapy treatment that utilizes nanoparticle albumin-bound technology to treat breast, lung, and pancreatic cancers. Following its landmark 74 billion acquisition of Celgene in 2019, BMS significantly expanded its portfolio to include blockbuster drugs like Revlimid and Pomalyst. The company's current growth strategy focuses on its New Product Portfolio, which includes cell therapies like Breyanzi and Abecma, as well as the first-in-class cardiac drug Camzyos. BMS is committed to advancing diverse therapeutic modalities, including small molecules, biologics, and cell-based therapies, to address unmet medical needs worldwide.